உடற்பயிற்சி சகிப்புத்தன்மை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

25
Tenax Therapeutics, Inc. (NASDAQ: TENX)announced positive data from its Phase 2 HELP Study that evaluated levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction.  Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Placebo-Controlled HELP Trial was published in the Journal of American College of Cardiology: Heart Failure.
The publication had a 84% responder rate during the open label phase as 37 or 44 patients met responder criteria and were randomized to levosimendan (n=18) or placebo (n=19).  Levosimendan did not significantly reduce the primary endpoint of exercise-PCWP but has reduced PCWP measured across all exercise stages.  The 6 week study design utilized invasive cardiovascular hemodynamics and secondary clinical endpoints that include a 6 minute walk test. ....

Daniel Burkhoff , Circulatory Support Research At Cardiovascular Foundation , Journal Of American College Cardiology , Tenax Therapeutics Inc , Tenax Therapeutics , Levosimendan Improves Hemodynamics , Exercise Tolerance , American College , Heart Failure , Mechanical Circulatory Support Research , Cardiovascular Research Foundation , Stuart Rich , Chief Medical Officer , Principal Investigator , இதழ் ஆஃப் அமெரிக்கன் கல்லூரி இருதயவியல் , உடற்பயிற்சி சகிப்புத்தன்மை , அமெரிக்கன் கல்லூரி , இதயம் தோல்வி , இருதய ஆராய்ச்சி அடித்தளம் , ஸ்டூவர்ட் பணக்கார , தலைமை மருத்துவ அதிகாரி , ப்ரிந்ஸிபல் புலனாய்வாளர் ,